Advertisement

Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome

Published:September 06, 2014DOI:https://doi.org/10.1016/j.ccep.2014.08.004

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cardiac Electrophysiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Van der Werf C.
        • van Langen I.M.
        • Wilde A.A.
        Sudden death in the young: what do we know about it and how to prevent?.
        Circ Arrhythm Electrophysiol. 2010; 3: 96-104
        • Schwartz P.J.
        • Stramba-Badiale M.
        • Crotti L.
        • et al.
        Prevalence of the congenital long-QT syndrome.
        Circulation. 2009; 120: 1761-1767
        • Postema P.G.
        About Brugada syndrome and its prevalence.
        Europace. 2012; 14: 925-928
        • Cerrone M.
        • Cummings S.
        • Alansari T.
        • et al.
        A clinical approach to inherited arrhythmias.
        Circ Cardiovasc Genet. 2012; 5: 581-590
        • Crotti L.
        • Marcou C.A.
        • Tester D.J.
        • et al.
        Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing.
        J Am Coll Cardiol. 2012; 60: 1410-1418
        • Tan H.L.
        • Bink-Boelkens M.T.
        • Bezzina C.R.
        • et al.
        A sodium-channel mutation causes isolated cardiac conduction disease.
        Nature. 2001; 409: 1043-1047
        • Postema P.G.
        • van den Berg M.P.
        • van Tintelen J.P.
        • et al.
        Founder mutations in the Netherlands. SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best described characterised families worldwide.
        Neth Heart J. 2009; 17: 422-428
        • Postema P.G.
        • Wolpert C.
        • Amin A.S.
        • et al.
        Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).
        Heart Rhythm. 2009; 6: 1335-1341
        • Woosley R.L.
        • Romero K.
        Assessing cardiovascular drug safety for clinical decision-making. Nature reviews.
        Cardiology. 2013; 10: 330-337
        • Postema P.G.
        • Neville J.
        • de Jong J.S.
        • et al.
        Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics.
        Europace. 2013; 15: 1042-1049
        • Sauer A.J.
        • Moss A.J.
        • McNitt S.
        • et al.
        Long QT syndrome in adults.
        J Am Coll Cardiol. 2007; 49: 329-337
        • Splawski I.
        • Shen J.
        • Timothy K.W.
        • et al.
        Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.
        Circulation. 2000; 102: 1178-1185
        • Hofman N.
        • Tan H.L.
        • Alders M.
        • et al.
        Yield of molecular and clinical testing for arrhythmia syndromes: report of 15 years’ experience.
        Circulation. 2013; 128: 1513-1521
        • Spazzolini C.
        • Mullally J.
        • Moss A.J.
        • et al.
        Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy.
        J Am Coll Cardiol. 2009; 54: 832-837
        • Zhang L.
        • Benson D.W.
        • Tristani-Firouzi M.
        • et al.
        Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.
        Circulation. 2005; 111: 2720-2726
        • Postema P.G.
        • Ritsema van Eck H.J.
        • Opthof T.
        • et al.
        IK1 modulates the U-wave: insights in a 100 year old enigma.
        Heart Rhythm. 2009; 6: 393-400
        • Viskin S.
        • Rosovski U.
        • Sands A.J.
        • et al.
        Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one.
        Heart Rhythm. 2005; 2: 569-574
        • Postema P.G.
        • de Jong J.S.
        • van der Bilt I.A.
        • et al.
        Accurate electrocardiographic assessment of the QT-interval: teach the tangent.
        Heart Rhythm. 2008; 5: 1015-1018
        • Postema P.G.
        • Wilde A.A.
        The measurement of the QT interval.
        Curr Cardiol Rev. 2014; 10: 287-294
        • Priori S.G.
        • Napolitano C.
        • Gasparini M.
        • et al.
        Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families.
        Circulation. 2000; 102: 2509-2515
        • Priori S.G.
        • Napolitano C.
        • Schwartz P.J.
        Low penetrance in the long-QT syndrome: clinical impact.
        Circulation. 1999; 99: 529-533
        • Viskin S.
        • Postema P.G.
        • Bhuiyan Z.A.
        • et al.
        The response of the QT-interval to the brief tachycardia provoked by standing. A bedside test for diagnosing Long-QT syndrome.
        J Am Coll Cardiol. 2010; 55: 1955-1961
        • Sy R.W.
        • van der Werf C.
        • Chattha I.S.
        • et al.
        Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands.
        Circulation. 2011; 124: 2187-2194
        • Adler A.
        • van der Werf C.
        • Postema P.G.
        • et al.
        The phenomenon of “QT stunning”: the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome.
        Heart Rhythm. 2012; 9: 901-908
        • Krahn A.D.
        • Healey J.S.
        • Chauhan V.
        • et al.
        Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER).
        Circulation. 2009; 120: 278-285
        • Amin A.S.
        • Giudicessi J.R.
        • Tijsen A.J.
        • et al.
        Variants in the 3’ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner.
        Eur Heart J. 2012; 33: 714-723
        • Bezzina C.R.
        • Barc J.
        • Mizusawa Y.
        • et al.
        Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.
        Nat Genet. 2013; 45: 1409
        • Wilde A.A.
        • Ackerman M.J.
        Exercise extreme caution when calling rare genetic variants novel arrhythmia syndrome susceptibility mutations.
        Heart Rhythm. 2010; 7: 1883-1885
        • Wilde A.A.
        • Postema P.G.
        • Di Diego J.M.
        • et al.
        The pathophysiological mechanism underlying Brugada syndrome. Depolarization versus repolarization.
        J Mol Cell Cardiol. 2010; 49: 543-553
        • Mizumaki K.
        • Fujiki A.
        • Tsuneda T.
        • et al.
        Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome.
        J Cardiovasc Electrophysiol. 2004; 15: 667-673
        • Veltmann C.
        • Schimpf R.
        • Echternach C.
        • et al.
        A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification.
        Eur Heart J. 2006; 27: 2544-2554
        • Probst V.
        • Wilde A.A.
        • Barc J.
        • et al.
        SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome.
        Circ Cardiovasc Genet. 2009; 2: 552-557
        • Rossenbacker T.
        • Carroll S.J.
        • Liu H.
        • et al.
        Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death.
        Heart Rhythm. 2004; 1: 610-615
        • Chockalingam P.
        • Rammeloo L.A.
        • Postema P.G.
        • et al.
        Fever-induced life-threatening arrhythmias in children harboring an SCN5A mutation.
        Pediatrics. 2011; 127: e239-e244
        • Watanabe H.
        • Koopmann T.T.
        • Le Scouarnec S.
        • et al.
        Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans.
        J Clin Invest. 2008; 118: 2260-2268
        • Bezzina C.
        • Veldkamp M.W.
        • van den Berg M.P.
        • et al.
        A single Na(+) channel mutation causing both long-QT and Brugada syndromes.
        Circ Res. 1999; 85: 1206-1213
        • Veldkamp M.W.
        • Viswanathan P.C.
        • Bezzina C.
        • et al.
        Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel.
        Circ Res. 2000; 86: E91-E97
        • Makita N.
        • Behr E.
        • Shimizu W.
        • et al.
        The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
        J Clin Invest. 2008; 118: 2219-2229
        • Roden D.M.
        Drug-induced prolongation of the QT interval.
        N Engl J Med. 2004; 350: 1013-1022
        • Brugada R.
        • Brugada J.
        • Antzelevitch C.
        • et al.
        Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.
        Circulation. 2000; 101: 510-515
        • Groome J.
        • Lehmann-Horn F.
        • Holzherr B.
        Open- and closed-state fast inactivation in sodium channels: differential effects of a site-3 anemone toxin.
        Channels (Austin). 2011; 5: 65-78
        • Veerman C.C.
        • Verkerk A.O.
        • Blom M.T.
        • et al.
        Slow delayed rectifier potassium current blockade contributes importantly to drug-induced Long QT syndrome.
        Circ Arrhythm Electrophysiol. 2013; 6: 1002-1009
        • Chockalingam P.
        • Crotti L.
        • Girardengo G.
        • et al.
        Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.
        J Am Coll Cardiol. 2012; 60: 2092-2099
        • Zeltser D.
        • Justo D.
        • Halkin A.
        • et al.
        Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
        Medicine (Baltimore). 2003; 82: 282-290
        • Postema P.G.
        • Tan H.L.
        • Wilde A.A.
        Ageing and Brugada syndrome: considerations and recommendations.
        J Geriatr Cardiol. 2013; 10: 75-81
        • Priori S.G.
        • Wilde A.A.
        • Horie M.
        • et al.
        HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes expert consensus statement on inherited primary arrhythmia syndromes.
        Heart Rhythm. 2013; 10: 1932-1963
        • Haugaa K.H.
        • Bos J.M.
        • Tarrell R.F.
        • et al.
        Institution-wide QT alert system identifies patients with a high risk of mortality.
        Mayo Clin Proc. 2013; 88: 315-325
        • Van Gorp V.
        • Danschutter D.
        • Huyghens L.
        • et al.
        Monitoring the safety of antiepileptic medication in a child with Brugada syndrome.
        Int J Cardiol. 2010; 145: e64-e67
        • Goldenberg I.
        • Moss A.J.
        • Peterson D.R.
        • et al.
        Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome.
        Circulation. 2008; 117: 2184-2191
        • Goldenberg I.
        • Moss A.J.
        • Bradley J.
        • et al.
        Long-QT syndrome after age 40.
        Circulation. 2008; 117: 2192-2201
        • Wilde A.A.
        • Kaufman E.S.
        • Shimizu W.
        • et al.
        Sodium channel mutations, risk of cardiac events, and efficacy of beta-blocker therapy in type 3 Long QT syndrome.
        Heart Rhythm. 2012; 9 ([abstract]): S321
        • Van den Berg M.P.
        • Haaksma J.
        • Veeger N.J.
        • et al.
        Diurnal variation of ventricular repolarization in a large family with LQT3-Brugada syndrome characterized by nocturnal sudden death.
        Heart Rhythm. 2006; 3: 290-295
        • Van den Berg M.P.
        • Wilde A.A.
        • Viersma J.W.
        • et al.
        Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome.
        J Cardiovasc Electrophysiol. 2001; 12: 630-636
        • Schwartz P.J.
        • Priori S.G.
        • Locati E.H.
        • et al.
        Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
        Circulation. 1995; 92: 3381-3386
        • Marquez M.F.
        • Bonny A.
        • Hernandez-Castillo E.
        • et al.
        Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review.
        Heart Rhythm. 2012; 9: 1995-2000
        • Viskin S.
        • Wilde A.A.
        • Guevara-Valdivia M.E.
        • et al.
        Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries.
        J Am Coll Cardiol. 2013; 61: 2383-2387
        • Viskin S.
        • Wilde A.A.
        • Tan H.L.
        • et al.
        Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry.
        Heart Rhythm. 2009; 6: 401-404